BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Education

MADISON HEIGHTS, Mich., April 30 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) as its July 2010 "Stock to Study" and Gilead Sciences, Inc. (Nasdaq: GILD) as its July "Undervalued Stock" for investors' informational and educational use.

"The committee chose Teva Pharmaceutical Industries because of the tremendous growth opportunities for generic drugs and the company's expertise and leadership in this industry," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the valuation of Gilead Sciences' stock was viewed as quite attractive in light of its growth." Check the BetterInvesting website in June for more details about these selections.

Committee members are Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Philip S. Dano, CFA; Donald E. Danko, CFA; Maury Elvekrog, CFA; Walter J. Kirchberger, CFA; and Marisa Lenhard, CFA.

As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases. For more information about investment education tools available to individual investors and investment clubs visit www.betterinvesting.org.

Follow us on Twitter and Facebook.

BetterInvesting Magazine is published monthly by BetterInvesting.


BetterInvesting is the brand identity of the National Association of Investors Corporation, a national, nonprofit association with members consisting of individual investors and investment clubs. Founded in 1951 and with headquarters in Madison Heights, Mich., BetterInvesting is considered the voice of the individual investor, as well as the pioneer of the modern investment club movement. BetterInvesting is dedicated to providing a sound program of investment education and information to help its members become successful long-term, lifetime investors. For more information about BetterInvesting, visit its website at www.betterinvesting.org or call toll free (877) 275-6242. For additional BetterInvesting data and news releases, visit the Media Center at www.betterinvesting.org/mediacenter.

SOURCE BetterInvesting

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.